Hirsutism and acne in polycystic ovary syndrome

被引:139
作者
Archer, JS [1 ]
Chang, RJ [1 ]
机构
[1] Univ Calif San Diego, Sch Med 0633, La Jolla, CA 92093 USA
关键词
acne; finasteride; flutamide; GnRH agonists; hirsutism; hyperandrogenism; oral contraceptive agents; polycystic ovarian syndrome; spironolactone;
D O I
10.1016/j.bpobgyn.2004.05.007
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Polycystic ovary syndrome (PCOS) is the most common endocrine abnormality affecting reproductive age women. Population-based studies estimate a prevalence of 5-10% [Obstet Gynecol 101 (2003) 995; Aust N Z J Obstet Gynaecol 41 (2001) 202]. The clinical characteristics of PCOS include hyperandrogenism, chronic anovulation, insulin resistance and infertility. Hyperandrogenism is generally manifested as hirsutism and acne. Both these clinical symptoms are treated with similar drug therapies, including oral contraceptive pills (OCPs), topical medications or antiandrogens such as spironolactone, flutamide and finasteride, as well as topical medications. Recent studies have shown that lower doses of these medications are as efficacious as high doses and have the advantage of decreased cost and an improved side-effect profile. Although hirsutism and acne can be considered cosmetic in nature, they cause significant social embarrassment and emotional distress. Physicians should be sensitive to these issues and approach patients in a caring and sympathetic manner.
引用
收藏
页码:737 / 754
页数:18
相关论文
共 53 条
[1]   The time has come to simplify the evaluation of the hirsute patient [J].
Azziz, R .
FERTILITY AND STERILITY, 2000, 74 (05) :870-872
[2]   The evaluation and management of hirsutism [J].
Azziz, R .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (05) :995-1007
[3]   LEUPROLIDE AND ESTROGEN VERSUS ORAL-CONTRACEPTIVE PILLS FOR THE TREATMENT OF HIRSUTISM - A PROSPECTIVE RANDOMIZED STUDY [J].
AZZIZ, R ;
OCHOA, TM ;
BRADLEY, EL ;
POTTER, HD ;
BOOTS, LR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3406-3411
[4]  
Balfour J A, 2001, Am J Clin Dermatol, V2, P197
[5]   Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism [J].
Bayram, F ;
Müderris, II ;
Güven, M ;
Kelestimur, FK .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 147 (04) :467-471
[6]  
Berson DS, 2003, CUTIS, V72, P5
[7]   A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women [J].
Carmina, E ;
Lobo, RA .
CLINICAL ENDOCRINOLOGY, 2002, 57 (02) :231-234
[8]   Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? [J].
Cibula, D ;
Hill, M ;
Fanta, M ;
Sindelka, G ;
Zivny, J .
HUMAN REPRODUCTION, 2001, 16 (05) :940-944
[9]   Clinical, endocrine and metabolic effects of acarbose, an α-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance [J].
Ciotta, L ;
Calogero, AE ;
Farina, M ;
De Leo, V ;
La Marca, A ;
Cianci, A .
HUMAN REPRODUCTION, 2001, 16 (10) :2066-2072
[10]   Safety evaluation of modern oral contraceptives -: Effects on lipoprotein and carbohydrate metabolism [J].
Crook, D ;
Godsland, I .
CONTRACEPTION, 1998, 57 (03) :189-201